Targeting Breast Cancer
A molecularly targeted therapeutic has been approved for use in combination with fulvestrant for treating certain men and women with breast cancer.
Progress Against Cancer
A molecularly targeted therapeutic has been approved for use in combination with fulvestrant for treating certain men and women with breast cancer.
A combination of an immunotherapy and a targeted therapeutic recently was approved by the FDA for patients advanced renal cell carcinoma (kidney cancer).
A molecularly targeted therapeutic was approved by the FDA to treating certain patients with urothelial carcinoma, the most common form of bladder cancer.
As Greek mythology tells us, the titan Prometheus was punished by the gods for giving fire to man. His sentence? Eternal torture. Each day, an eagle would eat his liver, which would grow back...
The FDA expanded the use of the immunotherapeutic atezolizumab in combination with carboplatin and etoposide for certain small-cell lung cancer patients.
The FDA approved the immunotherapeutic atezolizumab to treat certain patients who have locally advanced or metastatic triple-negative breast cancer.
Breast cancer can be a scary diagnosis. Even though mortality rates have declined in recent years in the United States, it is estimated that over 40,000 women and roughly 500 men will die from...
Providing a forum for innovative cancer researchers around the world, Singapore will hold its 11th Frontiers in Cancer Science (FCS) conference from November 4-6 at Academia at SingHealth. The conference is jointly organized by the...
The women bustle around a warm, colorful kitchen, making tamales for an upcoming family party. A woman in her 20s has received the distressing news that she has tested positive for the human papillomavirus...
Since its inception in 1993, the American Association of Cancer Research (AACR) Grants Program, in partnership with other nonprofit organizations, foundations, and pharmaceutical companies, has funded groundbreaking basic, translational, and clinical cancer research. In...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More